TIDMIXI
RNS Number : 6555X
IXICO plc
28 November 2017
28 November 2017
IXICO plc
("IXICO" or the "Company")
Strategic and Operational Update
Building scale and momentum with commercially-led growth
Notice of Final Results
IXICO plc (AIM: IXI), the digital technologies company serving
neuroscience, today outlines its commercially led growth strategy
as defined by Giulio Cerroni, Chief Executive Officer.
Giulio Cerroni, said: "Following my appointment in February 2017
I have completed an operational review of the Company. Below, I
have set out my plan to drive IXICO forward as a high growth and
scalable technology business focused on specialised areas of the
digital healthcare market. I have also provided an update on our
recent progress as we start to deliver on our objective to Build on
our core strengths and Grow our capabilities to Scale our
Company."
"I believe that IXICO is well positioned to benefit from a
number of market tailwinds as the biopharmaceutical industry looks
to leverage digital technologies in both drug development and the
way that medical care is delivered. Therefore, in my first months
my priority has been to ensure that as an organisation we have a
"razor-sharp" focus on our customer's needs, supporting their
business goals, better than our competitors.
"My review confirmed that our focus on neurological disorders in
a growing market will support our double digit organic growth
objectives. I also considered how to best leverage the Company's
existing technology and commercial assets. The outcome was a
commercially-led growth plan to deliver top-line growth through our
existing customer relationships and targeting new biopharmaceutical
customers to further progress our market penetration.
As part of our strategy we will look to supplement this organic
growth with the acquisition of complementary specialist
technologies, while keeping focused on our over-arching goal of an
accelerated path to profitability."
Strategy
Sector focus
We will build on IXICO's trusted position in providing
neuro-imaging technology enabled specialist services to the
biopharmaceutical industry. We have identified three key value
segments where IXICO's technology platform and capabilities are
mission critical and where our digital technologies could provide
considerable efficiencies and value:
-- Selecting patients for clinical trials
-- Assessing safety and efficacy in every phase of drug development
-- Post marketing surveillance of marketed medicines
Proven Technology
IXICO's digital technology platform has matured to a point where
we have demonstrated the capability, scale and experience to
provide new technology led services across all phases of drug
development and into post marketing surveillance. Consequently,
IXICO has become a long-term preferred partner, embedded in the
drug development value chain thereby creating a springboard for
growth and significant barrier to entry for our competitors.
Therapeutic area expertise
There is an urgent need to develop new and safe medicines to
meet the significant unmet medical need in brain-centred
neurological conditions such as Alzheimer's disease and Multiple
Sclerosis. An ageing population, increasing outsourcing, increasing
regulatory focus on patient safety for marketed drugs and a trend
towards patient outcome-based reimbursement are all additional
drivers that underpin our growth strategy.
We anticipate continued market penetration by intensifying our
commercial activities beyond Alzheimer's drug trials into adjacent
neurological diseases such as Multiple Sclerosis, Huntington's
disease, Parkinson's disease and rare diseases such as Progressive
Supranuclear Palsy (PSP).
Innovation
The biopharmaceutical industry requires streamlined, automated
platforms that provide regulatory compliant data collection and
analytics to provide deeper understanding of the disease, improved
personalisation and post marketing surveillance of their marketed
treatments. Increasing digitalisation is also providing new ways to
improve the efficiency of data collection including Real World Data
collection and analysis to support clinical decision making.
IXICO has a track record of innovative imaging data solutions
and is in a strong position to commercialise our new digital
technologies by improving the efficiency of clinical trials and
supporting post marketing surveillance. Our product development
plans have been aligned with our growth strategy to rapidly
progress our commercialisation of new innovative solutions in:
-- Wearable biosensors for inclusion in clinical trials as exploratory digital biomarkers
-- PET Image analysis in early phase clinical trials
-- Drug safety - our first platform to support post marketing
surveillance of drugs with known potential side effects such as
Progressive Multifocal Leukoencephalopathy (PML) in Multiple
Sclerosis
We are pleased to have announced two new wearable biosensor
agreements signed in recent months, which will make a material
contribution to top-line growth and our mid-term outlook.
Commercial momentum
Our strong performance in 2017 demonstrates that we are starting
to deliver on our growth plan and build commercial momentum. New
contracts won from both current and new customers provide early
vindication of our focus on commercial execution and operational
delivery. We have a growing pipeline of new contract opportunities
so are well positioned to make good progress on our path to
profitability.
I also believe that effective commercialisation of our new,
differentiated digital technology products and services can further
accelerate the growth projection of the business over the coming
years.
Path to profitability
With the opportunity to considerably scale our proven model,
IXICO has the potential to become a leader and partner of choice to
the global biopharmaceutical industry. As outlined, we will do this
by seeking to increase the rate of adoption of our digital
technology platform in the three key value segments identified. We
will achieve this through a commercially-led growth plan that is
already demonstrating considerable momentum with both current and
new Biopharma customers. We expect this momentum to accelerate with
both large Pharma and an increasing number of Biotech companies and
through new business partnerships with Contract Research
Organizations (CRO's).
Summary
We have defined and set out our growth strategy. Simply put, it
is building on our core strengths and growing our capabilities and
technologies into every stage of the drug development process
including post marketing surveillance in neurological disorders. To
accelerate our commercially-led growth plan, we will invest in our
operational delivery and our innovation roadmap to commercialise
new products and services to capitalise on the inflection point
reached by digital health technology.
On our path to profitability, we will seek to ensure that IXICO
captures its share of the value being created by incredibly
exciting and disruptive digital health tools, which are rapidly
gaining adoption for remote patient monitoring in chronic health
conditions.
IXICO will announce its final results for the year ended 30
September 2017 on Monday 11 December 2017.
For further information please contact:
IXICO plc
Giulio Cerroni, Chief Executive Tel: +44 20
Officer 3763 7499
Susan Lowther, Chief Financial Officer
FTI Consulting Limited (Investor Tel: +44 20
Relations) 3727 1000
Simon Conway/Mo Noonan
About IXICO
IXICO is the digital technologies company serving neuroscience.
Our mission is to transform the pursuit of improving brain health
through the application of digital technologies to neuroscience.
IXICO's specialist data analytics services are used by the global
pharmaceutical industry to select participants for clinical trials,
assess the safety and efficacy of new drugs in development and in
post marketing surveillance. Our neurological disease focus
includes Alzheimer's disease, Huntington's disease, Multiple
Sclerosis, Parkinson's disease and our integrated digital platform
encompasses the entire drug development lifecycle. It is a scalable
and secure infrastructure for the capture and analysis of
regulatory compliant clinical data to enable sponsors to make
rapid, better informed decisions. IXICO is also collaborating with
partners to develop new companion digital health products targeted
at improving patient outcomes.
More information is available on www.IXICO.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
UPDUBUKRBRAAUAA
(END) Dow Jones Newswires
November 28, 2017 02:01 ET (07:01 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024